Stock ATRA ATARA BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.5609 USD -1.28% Intraday chart for Atara Biotherapeutics, Inc. -10.11% +9.38%
May. 20 Sector Update: Health Care Stocks Ease Monday Afternoon MT
May. 20 Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
BU
Sector Update: Health Care Stocks Ease Monday Afternoon
MT
Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise
MT
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
BU
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
CI
Atara Biotherapeutics: Q1 Earnings Snapshot
AQ
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M
MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
BU
ATARA BIOTHERAPEUTICS, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)
AQ
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating
MT
Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc
CI
Atara Biotherapeutics: Q4 Earnings Snapshot
AQ
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
BU
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M
MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
North American Morning Briefing : Stocks Edge -2-
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATRA Stock
  4. News Atara Biotherapeutics, Inc.